Glenmede Trust’s Viridian Therapeutics VRDN Stock Holding History

Glenmede Trust’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,975	Closed	-$312K	–	1576
2026 Q1	$312K	Buy	15,975 +550	+4%	+$16.3K	﹤0.01%	1140
2025 Q4	$480K	Buy	+15,425	New	+$423K	﹤0.01%	960
2023 Q3	–	Sell	-13,451	Closed	-$342K	–	1369
2023 Q2	$342K	Hold	13,451	–	–	﹤0.01%	946
2023 Q1	$342K	Buy	13,451 +5,186	+63%	+$166K	﹤0.01%	951
2022 Q4	$241K	Buy	+8,265	New	+$190K	﹤0.01%	1041
2017 Q4	–	Sell	-117	Closed	-$16K	–	2802
2017 Q3	$16K	Buy	+117	New	+$19.7K	﹤0.01%	2042

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Glenmede Trust's VRDN Position: Q2 2026 in Review

Glenmede Trust sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 15,975 shares — an estimated $312K sold.

Glenmede Trust first reported a position in VRDN in Q3 2017 and held it in 6 quarters. The position peaked at $480K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Glenmede Trust reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Glenmede Trust sold 15,975 Viridian Therapeutics shares in Q2 2026, an estimated $312K.
Glenmede Trust first reported a position in Viridian Therapeutics in Q3 2017 and held it in 6 quarters.
Glenmede Trust's Viridian Therapeutics position peaked at $480K in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.